---
schema_version: "secwatch.filing_event.v1"
accession: "0001787400-26-000012"
form_type: "8-K"
ticker: "NKTX"
cik: "0001787400"
company_name: "Nkarta, Inc."
filed_at: "2026-05-12T20:04:35+00:00"
generated_at: "2026-05-12T21:37:11.426186+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Nkarta Q1 net loss $27.8M ($0.37/shr); cash $266.7M; advances NKX019 trials

## Summary
- Cash, equivalents, and investments $266.7M as of Mar 31, 2026; expected to fund operations into 2029.
- Net loss $27.8M ($0.37 per basic/diluted share) for Q1 2026; R&D expense $25.0M, G&A $5.9M.
- FDA agreed to protocol amendments allowing outpatient dosing in community settings, re-dosing, and adding RA to Ntrust-2.
- Enrollment ongoing at 4 billion cells per dose (12B total) across Ntrust-1 and Ntrust-2 for multiple autoimmune indications.
- Initial clinical data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026.

## SEC filing metadata
- accession: 0001787400-26-000012
- form_type: 8-K
- ticker: NKTX
- cik: 0001787400
- company_name: Nkarta, Inc.
- filed_at: 2026-05-12T20:04:35+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787400/000178740026000012/0001787400-26-000012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787400/000178740026000012/nktx-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001787400-26-000012
- JSON: https://secwatch.observer/filing/0001787400-26-000012.json
- Plain text: https://secwatch.observer/filing/0001787400-26-000012.txt

## Key facts
- Earnings Releases
  Nkarta, Inc. reported first quarter ended March 31, 2026 results: net income $27.8 million, or $0.37 per basic and diluted share, EPS $0.37 per basic and diluted share. Guidance reaffirmed.
  - Period: first quarter ended March 31, 2026
  - Net income: $27.8 million, or $0.37 per basic and diluted share
  - EPS: $0.37 per basic and diluted share
  - Guidance: reaffirmed
  - Result: reported results
  source text: Nkarta, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787400/000178740026000012/0001787400-26-000012-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.